Technology | Breast Biopsy Systems | July 24, 2019

Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System

Clinicians can use tomosynthesis guidance to calculate 3-D coordinates of suspicious breast lesion

Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System

July 24, 2019 – Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its Tomosynthesis Biopsy option for the Aspire Cristalle mammography system. This new option uses tomosynthesis guidance to calculate 3-D coordinates of a suspicious lesion in the breast, in addition to the traditional stereotactic method. This allows radiologists to accurately complete biopsy of suspicious areas to conduct a pathological examination and inform the diagnosis and care plan. Clinicians will now be able to enhance diagnostic care for patients by using Tomosynthesis Biopsy to target a lesion previously undetectable on images from full field digital mammography (FFDM) alone.  

Clinicians can realize the following benefits when using the Tomosynthesis Biopsy in addition to Stereotactic Biopsy on the Aspire Cristalle with DBT mammography system:

  • Clinical Confidence: Clinicians will have more options to deliver enhanced diagnosis to patients. Now with Tomo Biopsy, targeting is improved by identifying the area of concern directly on the corresponding tomosynthesis slice;
  • Ease-of-Use: High-resolution dual display system, targeting guide function on stereo images, various image processing and other useful functions designed to make targeting accurate and easy; and
  • Increased Efficiency: Tomo Biopsy leads to a more efficient workflow with the potential to decrease exam times, as clinicians can use a single click to calculate 3-D coordinates compared to targeting the same lesion on two images with Stereotactic Biopsy. By using tomosynthesis images for targeting instead of traditional 2-D clinicians are also afforded the increased diagnostic confidence that comes hand-in-hand with tomosynthesis use.

The Fujifilm Aspire Cristalle with DBT combines state-of-the-art, Hexagonal Close Pattern (HCP) capture technology and intelligent image processing, optimizing dose and contrast based on individual breast composition. The result is low dose and fast acquisition of high-quality images for all breast types. In addition, patients can experience a noticeable improvement in comfort during procedures with Fujifilm’s patented, flexible comfort paddle design, which provides gentle and even compression that is designed to adapt to patient curves.

Fujifilm representatives are presenting Tomosynthesis Biopsy at Fujifilm’s booth at the Association for Medical Imaging Management (AHRA) annual meeting, July 21-24 in Denver.

For more information: www.fujifilmusa.com

Related Content

Ceiling-mounted X-ray system includes MyExam Companion intelligent user interface to guide technologist through exam workflow
News | X-Ray | October 26, 2020
October 26, 2020 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the...
Mammography, which is an X-ray picture of the breast, is efficient also for women over the age of 70.

Getty Images

News | Mammography | October 22, 2020
October 22, 2020 — ...
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rebrand reflects Volpara Health's mission to prevent advanced-stage breast cancer
News | Breast Imaging | October 19, 2020
October 19, 2020 — Volpara Solutions, a leader in AI-powered breast density assessment, announced that it has changed
More than 600,000 women die of advanced breast cancer annually. (1) There is a safe, universally obtainable method to reduce this terrible toll according to MammaCare Foundation scientist Mark Kane Goldstein, Ph.D.

Module 1

News | Women's Health | October 15, 2020
October 15, 2020 — More than 600,000 women die of advanced breast cancer annually. ...